Events and Presentations Events and Presentations Past Events JMP Securities Life Sciences Conference Jun 15, 2022 at 2:00 PM EDT Listen to webcast BofA Securities 2022 Healthcare Conference May 10, 2022 at 10:40 AM PDT Listen to webcast Supporting Materials View Presentation 2.2 MB Presentations Corporate Presentation - August 2022 ASH 2021 – A Novel LAIR-1 Antibody Target Acute Myeloid Leukemia (AML) Stem Cells ASH 2021 – Siglec-15 is a Novel Immunomodulatory Protein and Therapeutic Target in Acute Lymphoblastic Leukemia NextCure Virtual Oncology Pipeline Update Presentation SITC 2021 Oral Presentation: Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors SITC 2021 Poster - Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization SITC 2021 Poster - NC410, a fusion protein of LAIR-2 fused to human IgG1 Fc is safe and tolerable with evidence of immune modulation in subjects with advanced solid tumors 19th Annual Morgan Stanley Global Healthcare Conference Presentation H. C. Wainwright 23rd Annual Global Investment Conference Presentation JMP Securities Life Sciences Conference Presentation NC410 ASCO 2021 Poster BofA Securities 2021 Virtual Health Care Conference Presentation Truist Securities Life Sciences Summit Presentation Needham Healthcare Conference Presentation NC762 AACR 2021 Poster NextCure Virtual R&D Update Presentation NC410 (Tian) SITC 2020 Poster NC410 (Horn) SITC 2020 Poster NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting NextCure Presents Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of SITC NextCure Hosts and Webcast Event at the 34th Annual Meeting of SITC NextCure Presents Preclinical Data on NC318, a Novel Immunomedicine Targeting Siglec-15, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting (PDF) Tools
Events and Presentations Past Events JMP Securities Life Sciences Conference Jun 15, 2022 at 2:00 PM EDT Listen to webcast BofA Securities 2022 Healthcare Conference May 10, 2022 at 10:40 AM PDT Listen to webcast Supporting Materials View Presentation 2.2 MB Presentations Corporate Presentation - August 2022 ASH 2021 – A Novel LAIR-1 Antibody Target Acute Myeloid Leukemia (AML) Stem Cells ASH 2021 – Siglec-15 is a Novel Immunomodulatory Protein and Therapeutic Target in Acute Lymphoblastic Leukemia NextCure Virtual Oncology Pipeline Update Presentation SITC 2021 Oral Presentation: Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors SITC 2021 Poster - Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization SITC 2021 Poster - NC410, a fusion protein of LAIR-2 fused to human IgG1 Fc is safe and tolerable with evidence of immune modulation in subjects with advanced solid tumors 19th Annual Morgan Stanley Global Healthcare Conference Presentation H. C. Wainwright 23rd Annual Global Investment Conference Presentation JMP Securities Life Sciences Conference Presentation NC410 ASCO 2021 Poster BofA Securities 2021 Virtual Health Care Conference Presentation Truist Securities Life Sciences Summit Presentation Needham Healthcare Conference Presentation NC762 AACR 2021 Poster NextCure Virtual R&D Update Presentation NC410 (Tian) SITC 2020 Poster NC410 (Horn) SITC 2020 Poster NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting NextCure Presents Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of SITC NextCure Hosts and Webcast Event at the 34th Annual Meeting of SITC NextCure Presents Preclinical Data on NC318, a Novel Immunomedicine Targeting Siglec-15, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting (PDF)
BofA Securities 2022 Healthcare Conference May 10, 2022 at 10:40 AM PDT Listen to webcast Supporting Materials View Presentation 2.2 MB
ASH 2021 – Siglec-15 is a Novel Immunomodulatory Protein and Therapeutic Target in Acute Lymphoblastic Leukemia
SITC 2021 Oral Presentation: Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors
SITC 2021 Poster - Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization
SITC 2021 Poster - NC410, a fusion protein of LAIR-2 fused to human IgG1 Fc is safe and tolerable with evidence of immune modulation in subjects with advanced solid tumors
NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting
NextCure Presents Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of SITC
NextCure Presents Preclinical Data on NC318, a Novel Immunomedicine Targeting Siglec-15, at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting (PDF)
